![](images/graphics/blank.gif)
Unresectable hepatocellular carcinoma
-
Combination therapy is the primary treatment for unresectable hepatocellular carcinoma (u-HCC). The hepatic functional reserve is also critical in the treatment of HCC. In this study, u-HCC was treated with combined hepatic arterial infusion chemotherapy (HAIC), tyrosine kinase inhibitors (TKIs), and programmed cell death protein-1 (PD-1) inhibitors to analyze the therapeutic response, progression-free survival (PFS), and safety.
10p
vishanshan
27-06-2024
2
1
Download
-
To compare the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined Lenvatinib plus Camrelizumab (TLC) in unresectable hepatocellular carcinoma (uHCC) with those of TACE alone.
10p
vikoch
27-06-2024
3
1
Download
-
Trans-arterial hemoembolization (TACE) usually indicated for unresectable hepatocellular carcinoma (HCC) on purpose as a bridging, downstaging or palliative treatment. Liver Imaging Reporting and Data Systems Treatment Response (LR-TR) was created to evaluate each lesion post-TACE, which has localized and is suitable for determining whether the tumor is still viable or Non-viable.
8p
vicarlos
16-05-2024
1
0
Download
-
Cancer therapy has evolved from non-specific cytotoxic agents to a selective, mechanism-based approach that includes targeted agents and immunotherapy. Although the response to targeted therapies for unresectable hepatocellular carcinoma (HCC) is acceptable with the improved survival, the high tumor recurrence rate and drug-related side effects continue to be problematic.
8p
vileonardodavinci
23-12-2023
9
4
Download
-
Our objective was to assess the efficacy and safety of initial hepatic arterial infusion of chemotherapy combined with transarterial chemoembolisation using camrelizumab-eluting Callisphere beads (camrelizumab-DEBTACE) for treating unresectable hepatocellular carcinoma (HCC).
9p
vileonardodavinci
23-12-2023
7
2
Download
-
To compare the efcacy and safety of TACE combined with Donafenib and Toripalimab versus TACE combined with Sorafenib in the treatment of unresectable hepatocellular carcinoma (HCC), aiming to guide personalized treatment strategies for HCC and improve patient prognosis.
11p
vialfrednobel
23-12-2023
4
3
Download
-
Immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of hepatocellular carcinoma (HCC). However, long-term survival outcomes and treatment response of HCC patients undergoing immunotherapy is unpredictable. The study aimed to evaluate the role of alpha-fetoprotein (AFP) combined with neutrophil-tolymphocyte ratio (NLR) to predict the prognosis and treatment response of HCC patients receiving ICIs.
11p
visharma
20-10-2023
7
3
Download
-
To understand the proportion of uHCC (unresectable hepatocellular carcinoma) patients who achieve successful conversion resection in a high-volume setting with state of the art treatment options.
14p
visharma
20-10-2023
5
2
Download
-
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death, worldwide. The predominant causative factor for HCC is hepatitis B virus (HBV) infection. We conducted a meta-analysis to estimate the efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the first-line treatment of the unresectable HCC and to evaluate the benefits of different geographic regions and etiology stratifications.
11p
visharma
20-10-2023
8
3
Download
-
Several cancer immunotherapies that target the PD-L1/PD-1 pathway show promising clinical activity in patients with hepatocellular carcinoma (HCC). However, the standard of care in first-line treatment with atezolizumab (anti-PD-L1 therapy) in combination with bevacizumab is associated with a limited objective response rate.
9p
vioracle
29-09-2023
7
3
Download
-
Clinical trials have shown that anti-PD1 therapy, either as a monotherapy or in combination, is effective and well-tolerated in patients with recurrent or unresectable hepatocellular carcinoma (HCC). In this study, we aimed to investigate the prognostic value of immune-nutritional biomarkers in measuring the effects of anti-PD1 therapy in these patients.
14p
vioracle
29-09-2023
9
3
Download
-
Although the standard therapy for advanced-stage hepatocellular carcinoma (HCC) is systemic chemotherapy, the combination of atezolizumab and bevacizumab (atezo+bev) with a high objective response rate may lead to conversion to resection in patients with initially unresectable HCC. This study aims to evaluate the efficacy of atezo+bev in achieving conversion surgery and prolonged progression-free survival (PFS) for initially unresectable HCC.
7p
vioracle
29-09-2023
5
2
Download
-
To investigate the maximum tolerated dose (MTD) of apatinib delivered during and after intensitymodulated radiotherapy (IMRT) for unresectable hepatocellular carcinoma (HCC).
7p
vikolindagrabar
27-07-2022
4
1
Download
-
The purpose of this study was to explore the efficacy and safety of transarterial chemoembolization (TACE) combined with apatinib and camrelizumab (TACE+AC) for unresectable hepatocellular carcinoma (HCC), and the impact of the timing of the combination on it.
10p
vikolindagrabar
27-07-2022
5
2
Download
-
The aim of this retrospective study was to assess the efficacy and safety of pembrolizumab plus lenvatinib plus hepatic arterial infusion chemotherapy (HAIC) versus pembrolizumab plus lenvatinib in selected populations of patients with treatment-naive uHCC exhibiting programmed cell death ligand-1 (PD-L1) staining.
13p
vimahuateng
26-11-2021
6
2
Download
-
The oncogenic PI3K/Akt/mTOR pathway is frequently activated in HCC. Data on the mTOR inhibitor, temsirolimus, is limited in HCC patients with concomitant chronic liver disease. The objectives of this study were: (1) In phase I, to determine DLTs and MTD of temsirolimus in HCC patients with chronic liver disease; (2) In phase II, to assess activity of temsirolimus in HCC, and (3) to explore potential biomarkers for response.
11p
vialabama2711
21-09-2020
11
1
Download
-
Microwave ablation (MWA) is widely used to treat unresectable primary and secondary malignancies of the liver, and a limited number of studies indicate that ablation can cause not only necrosis at the in situ site but also an immunoreaction of the whole body.
10p
vimoscow2711
29-08-2020
5
1
Download
-
The aim of this study was to determine the clinical benefit of transhepatic arterial chemoembolization (TACE) with or without recombinant human adenovirus type 5 (H101) administration for the treatment of patients with hepatocellular carcinoma (HCC).
9p
vimoscow2711
29-08-2020
10
1
Download
-
Stereotactic body radiation therapy (SBRT) has been an emerging non-invasive treatment modality for patients with hepatocellular carcinoma (HCC) when curative treatments cannot be applied. In this study, we report our clinical experience with Cyberknife SBRT for unresectable HCC and evaluate the efficacy and clinical outcomes of this highly sophisticated treatment technology.
10p
vinaypyidaw2711
26-08-2020
14
2
Download
-
Solid tumors, such as hepato-pancreato-biliary cancer, develop tumor hypoxia with tumor growth. Despite advances in surgery, a majority of these patients are in an unresectable condition. At this stage standard cytotoxic chemotherapy regimens are applied with limited success.
6p
vimale2711
25-08-2020
4
1
Download
CHỦ ĐỀ BẠN MUỐN TÌM
![](images/graphics/blank.gif)